Cargando…

The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa

BACKGROUND: A 4-month first-line treatment regimen for tuberculosis disease (TB) is expected to have a direct impact on patient outcomes and societal costs, as well as an indirect impact on Mycobacterium tuberculosis transmission. We aimed to estimate this combined impact in a high TB-burden country...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knight, Gwenan M., Gomez, Gabriela B., Dodd, Peter J., Dowdy, David, Zwerling, Alice, Wells, William A., Cobelens, Frank, Vassall, Anna, White, Richard G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696677/ https://www.ncbi.nlm.nih.gov/pubmed/26717007 http://dx.doi.org/10.1371/journal.pone.0145796

Ejemplares similares

Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
por: Shrestha, Sourya, et al.
Publicado: (2014)

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
por: Gomez, G. B., et al.
Publicado: (2016)

Tuberculosis Prevention in South Africa
por: Knight, Gwenan M., et al.
Publicado: (2015)

Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
por: Fofana, Mariam O., et al.
Publicado: (2014)

Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations
por: Zwerling, Alice, et al.
Publicado: (2014)

A Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant Tuberculosis
por: Fofana, Mariam O., et al.
Publicado: (2017)

Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling
por: Dowdy, D. W., et al.
Publicado: (2014)

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
por: Sweeney, Sedona, et al.
Publicado: (2022)

Mathematical Modelling and Tuberculosis: Advances in Diagnostics and Novel Therapies
por: Zwerling, Alice, et al.
Publicado: (2015)

Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making
por: Knight, Gwenan M., et al.
Publicado: (2015)

Examining Approaches to Estimate the Prevalence of Catastrophic Costs Due to Tuberculosis from Small-Scale Studies in South Africa
por: Sweeney, Sedona, et al.
Publicado: (2020)

Measuring Stigma to Assess the Social Justice Implications of Health-Related Policy Decisions: Application to Novel Treatment Regimens for Multidrug-Resistant Tuberculosis
por: Dowdy, David W., et al.
Publicado: (2020)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
por: Lai, Wendy A., et al.
Publicado: (2022)

Catastrophic costs potentially averted by tuberculosis control in India and South Africa: a modelling study
por: Verguet, Stéphane, et al.
Publicado: (2017)

Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness
por: Nsengiyumva, Ntwali Placide, et al.
Publicado: (2022)

Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa
por: Bozzani, Fiammetta M., et al.
Publicado: (2020)

Cost-effectiveness of Xpert MTB/RIF for tuberculosis diagnosis in South Africa: a real-world cost analysis and economic evaluation
por: Vassall, Anna, et al.
Publicado: (2017)

Using system dynamics modelling to estimate the costs of relaxing health system constraints: a case study of tuberculosis prevention and control interventions in South Africa
por: Bozzani, Fiammetta M, et al.
Publicado: (2021)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
por: Ilaiwy, Ghassan, et al.
Publicado: (2021)

Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis
por: Kendall, Emily A, et al.
Publicado: (2017)

Understanding spending trends for tuberculosis
por: Zwerling, Alice
Publicado: (2020)

Predicting the Long-Term Impact of Antiretroviral Therapy Scale-Up on Population Incidence of Tuberculosis
por: Dodd, Peter J., et al.
Publicado: (2013)

Yield of household contact tracing for tuberculosis in rural South Africa
por: Little, Kristen M., et al.
Publicado: (2018)

Correction: Predicting the Long-Term Impact of Antiretroviral Therapy Scale-Up on Population Incidence of Tuberculosis
por: Dodd, Peter J., et al.
Publicado: (2013)

Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States
por: Winston, Carla A., et al.
Publicado: (2023)

Estimating the Impact of Tuberculosis Case Detection in Constrained Health Systems: An Example of Case-Finding in South Africa
por: Sumner, Thomas, et al.
Publicado: (2019)

Tuberculosis screening costs and cost-effectiveness in high-risk groups: a systematic review
por: Alsdurf, H., et al.
Publicado: (2021)

Revisiting annual screening for latent tuberculosis infection in healthcare workers: a cost-effectiveness analysis
por: Mullie, Guillaume A., et al.
Publicado: (2017)

How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India
por: Azman, Andrew S, et al.
Publicado: (2014)

The impact of the roll-out of rapid molecular diagnostic testing for tuberculosis on empirical treatment in Cape Town, South Africa
por: Hermans, Sabine, et al.
Publicado: (2017)

Application of provincial data in mathematical modelling to inform sub-national tuberculosis program decision-making in South Africa
por: Hippner, Piotr, et al.
Publicado: (2019)

Cost-effectiveness of routine adolescent vaccination with an M72/AS01(E)-like tuberculosis vaccine in South Africa and India
por: Harris, Rebecca C., et al.
Publicado: (2022)

Complexity and evidence in health sector decision-making: lessons from tuberculosis infection prevention in South Africa
por: Perera, Shehani, et al.
Publicado: (2022)

Informing decision-making for universal access to quality tuberculosis diagnosis in India: an economic-epidemiological model
por: Sohn, Hojoon, et al.
Publicado: (2019)

Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
por: Knight, Gwenan M, et al.
Publicado: (2019)

Feasibility, Yield, and Cost of Active Tuberculosis Case Finding Linked to a Mobile HIV Service in Cape Town, South Africa: A Cross-sectional Study
por: Kranzer, Katharina, et al.
Publicado: (2012)

What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?
por: Pooran, Anil, et al.
Publicado: (2013)

The patient costs of care for those with TB and HIV: a cross-sectional study from South Africa
por: Mudzengi, Don, et al.
Publicado: (2017)

A user-friendly, open-source tool to project impact and cost of diagnostic tests for tuberculosis
por: Dowdy, David W, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1jgt2rkgijkfilckigpevkeb1p